Form 8-K - Current report:
SEC Accession No. 0001411685-25-000007
Filing Date
2025-01-14
Accepted
2025-01-14 17:16:28
Documents
15
Period of Report
2025-01-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtgn-20250114.htm   iXBRL 8-K 24640
2 EX-99.1 ex-991ph284phase2pr20250114.htm EX-99.1 19311
6 imagea.jpg GRAPHIC 9938
  Complete submission text file 0001411685-25-000007.txt   187171

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtgn-20250114.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtgn-20250114_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtgn-20250114_pre.xml EX-101.PRE 12510
17 EXTRACTED XBRL INSTANCE DOCUMENT vtgn-20250114_htm.xml XML 2729
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

EIN.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 25530216
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)